Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis

Blood

Volumn 102, Issue 3, 2003, Pages 1028-1034

  Mathas, Stephan ^a   Lietz, Andreas ^b   Janz, Martin ^b   Hinz, Michael ^b   Jundt, Franziska ^b   Scheidereit, Claus ^b   Bommert, Kurt ^b   Dörken, Bernd ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENATE SODIUM; ARSENIC; ARSENIC TRIOXIDE; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; CHEMOKINE RECEPTOR CCR7; GENE PRODUCT; I KAPPA B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; PROTEIN C IAP2; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG; ARSENITE SODIUM; ARSENOUS ACID DERIVATIVE; CHUK PROTEIN, HUMAN; CHUK PROTEIN, MOUSE; IKBKB PROTEIN, HUMAN; IKBKB PROTEIN, MOUSE; IKBKE PROTEIN, HUMAN; IKBKE PROTEIN, MOUSE; ORGANOARSENIC DERIVATIVE; OXIDE; PROTEIN SERINE THREONINE KINASE; SODIUM DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL PROTECTION; CELL STRAIN L540CY; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INHIBITION KINETICS; LYMPHOMA; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REED STERNBERG CELL; STRAIN IDENTIFICATION; XENOTRANSPLANTATION; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; XENOGRAFT;

ANIMALS; APOPTOSIS; ARSENIC; ARSENICALS; ARSENITES; DOWN-REGULATION; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMANS; I-KAPPA B KINASE; MICE; MICE, SCID; NF-KAPPA B; OXIDES; PROTEIN-SERINE-THREONINE KINASES; REED-STERNBERG CELLS; SODIUM COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0042744800     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1154     Document Type: Article

References (48)

1. Aronson SM. Arsenic and old myths. R I Med. 1994;77:233-234.
2. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist. 2001;6(suppl 2):3-10.
3. Kasten FH. Paul Ehrlich: pathfinder in cell biology, 1: chronicle of his life and accomplishments in immunology, cancer research, and chemotherapy. Biotech Histochem. 1996;71:2-37.
4. Denise H, Barrett MP. Uptake and mode of action of drugs used against sleeping sickness. Biochem Pharmacol. 2001;61:1-5.
5. Forkner C, McNair-Scott TF. Arsenic as a therapeutic agent in chronic myeloid leukemia. JAMA. 1931;97:3-5.
6. Farber EM. History of the treatment of psoriasis. J Am Acad Dermatol. 1992;27:640-645.
7. Chen CJ, Chen CW, Wu MM, Kuo TL. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer. 1992;66:888-892.
8. Jackson R, Grainge JW. Arsenic and cancer. Can Med Assoc J. 1975;113:396-401.
9. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.
10. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist. 2001; 6(suppl 2):22-28.
11. Novick SC, Warrell RP Jr. Arsenicals in hematologic cancers. Semin Oncol. 2000;27:495-501.
12. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62:3893-3903.
13. Zhu J, Koken MH, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94: 3978-3983.
14. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-l transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000;96:2849-2855.
15. Liu Y, Guyton KZ, Gorospe M, Xu Q, Lee JC, Holbrook NJ. Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radic Biol Med. 1996;21:771-781.
16. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 1996;15:6269-6279.
17. Maeda H, Hori S, Nishitoh H, et al. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res. 2001;61:5432-5440.
18. Jing Y, Dai J, Chalmers Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94:2102-2111.
19. Snow ET. Metal carcinogenesis: mechanistic implications. Pharmacol Ther. 1992;53:31-65.
20. Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000;275:36062-36066.
21. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol. 2000;18:621-663.
22. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. 1995;9:2723-2735.
23. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18: 6938-6947.
24. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347.
25. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2966.
26. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood. 1999;94:3129-3134.
27. Cabannes E, Khan G, Aillet F. Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaB-alpha. Oncogene. 1999;18:3063-3070.
28. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dörken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18:943-953.
29. Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002;21:4104-4113.
30. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic-trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
31. Hinz M, Löser P, Mathas S, Krappmann D, Dörken B, Scheidereit C. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD66, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood. 2001;97:2798-2807.
32. Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002;196:605-617.
33. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998; 281:1680-1683.
34. Höpken UE, Foss H-D, Meyer D, et al. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood. 2002;99:1109-1116.
35. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241-246.
36. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science. 1993;259:1912-1915.
37. Dürkop H, Foss HD, Demel G, Klotzbach H, Hahn C, Stein H. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood. 1999;93: 617-623.
38. Puccetti E, Guller S, Orleth A, et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res. 2000;60:3409-3413.
39. Uslu R, Sanli UA, Sezgin C, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res. 2000;6:4957-4964.
40. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS. A requirement for NF-kappaB activation in Bcr-Abi-mediated transformation. Genes Dev. 1998;12:968-981.
41. Portis T, Harding JC, Ratner L. The contribution of NF-κB activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood. 2001;98: 1200-1208.
42. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 2001;20:4188-4197.
43. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93:278-283.
44. Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/interferon specifically reverses two distinct gene networks critical for the survival of HTLV-1 infected leukemic cells. Blood. 2003;101:4576-4582.
45. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000; 20:2687-2695.
46. Wang CY, Guttridge DC, Mayo MW, Baldwin AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999;19:5923-5929.
47. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adapter proteins that regulates life and death. Genes Dev. 1998;12:2821-2830.
48. Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance: enhanced antitumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 1999; 5:412-417.